New York State Common Retirement Fund Acquires 12,380 Shares of Emergent Biosolutions, Inc. (EBS)
New York State Common Retirement Fund boosted its holdings in Emergent Biosolutions, Inc. (NYSE:EBS) by 14.3% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 98,770 shares of the biopharmaceutical company’s stock after acquiring an additional 12,380 shares during the period. New York State Common Retirement Fund owned about 0.24% of Emergent Biosolutions worth $3,349,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also modified their holdings of EBS. Vanguard Group Inc. lifted its holdings in Emergent Biosolutions by 6.7% in the first quarter. Vanguard Group Inc. now owns 3,773,200 shares of the biopharmaceutical company’s stock worth $109,574,000 after acquiring an additional 238,194 shares during the last quarter. State Street Corp lifted its holdings in Emergent Biosolutions by 17.2% in the first quarter. State Street Corp now owns 1,452,472 shares of the biopharmaceutical company’s stock worth $42,180,000 after acquiring an additional 213,500 shares during the last quarter. Rice Hall James & Associates LLC lifted its holdings in Emergent Biosolutions by 26.1% in the second quarter. Rice Hall James & Associates LLC now owns 669,617 shares of the biopharmaceutical company’s stock worth $22,707,000 after acquiring an additional 138,611 shares during the last quarter. Aberdeen Asset Management PLC UK lifted its holdings in Emergent Biosolutions by 7.3% in the second quarter. Aberdeen Asset Management PLC UK now owns 1,737,470 shares of the biopharmaceutical company’s stock worth $58,918,000 after acquiring an additional 118,894 shares during the last quarter. Finally, New Amsterdam Partners LLC NY bought a new position in Emergent Biosolutions in the second quarter worth about $3,331,000. 85.33% of the stock is currently owned by hedge funds and other institutional investors.
A number of brokerages have issued reports on EBS. Zacks Investment Research cut shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Friday, August 11th. BidaskClub raised shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a report on Saturday, June 24th. Finally, Wells Fargo & Co reissued an “outperform” rating and issued a $43.00 target price (up previously from $41.00) on shares of Emergent Biosolutions in a report on Saturday, September 30th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $45.00.
In other Emergent Biosolutions news, Chairman Fuad El-Hibri sold 25,000 shares of the business’s stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $40.50, for a total value of $1,012,500.00. Following the transaction, the chairman now directly owns 1,555,216 shares in the company, valued at $62,986,248. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Ronald Richard sold 22,415 shares of the business’s stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $40.00, for a total transaction of $896,600.00. Following the completion of the transaction, the director now owns 24,676 shares in the company, valued at $987,040. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 205,227 shares of company stock worth $7,906,470. Company insiders own 16.50% of the company’s stock.
Shares of Emergent Biosolutions, Inc. (NYSE EBS) opened at 40.30 on Friday. The firm has a market cap of $1.66 billion, a price-to-earnings ratio of 25.67 and a beta of 1.26. Emergent Biosolutions, Inc. has a 52 week low of $24.47 and a 52 week high of $41.46. The firm has a 50 day moving average of $39.02 and a 200 day moving average of $34.22.
Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.13 EPS for the quarter, missing the Zacks’ consensus estimate of $0.26 by ($0.13). The firm had revenue of $100.77 million during the quarter, compared to analyst estimates of $111.57 million. Emergent Biosolutions had a net margin of 13.42% and a return on equity of 14.50%. Emergent Biosolutions’s quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.05) earnings per share. Equities analysts predict that Emergent Biosolutions, Inc. will post $1.54 earnings per share for the current fiscal year.
About Emergent Biosolutions
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions, Inc. (NYSE:EBS).
Receive News & Stock Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related stocks with our FREE daily email newsletter.